Finally, IGF-I treatment was effective in increasing FOXO1 activity, thereby suggesting that it could be considered as a potential treatment in CF patients, possibly to prevent and treat CFRD. This evidence concerns the gene FOXO1 and cystic fibrosis-related diabetes.